Equate study group 1 Other intervention in the manage group 1 Repeated study Studies integrated final systematic rewiew (n = 4) 1 Randomized controlled study two Historical manage studies 1 Retrospective control studyFigure 1. Modified Flow Chart In accordance with the QUOROM Statement Summarizing the number of Screened Abstracts and Identified Relevant Articles During the Critique ProcessHepat Mon. 2013;13(four):eZheng Y et al.Table 1. The Baseline Traits with the 4 Trials11 P Dai et al. (2004) 9 C NM 31 PLamivudine and breast cancer patients with HBsAg positiveYeo et al. (2004) 61 C 61/No. of PatientsPLong et al. (2011) C 21 21/Gender, female/male Baseline ALT Median (Variety), IU/l HBsAg, /HBsAb, /Age, y, Median (Range)NM47 (3658) 14 (1231) 11/0 2/9 9/43 (2755) 15 (654) 9/0 1/8 8/31/46 (3168)28 (13137) 31/0 NM NM NM NM NM NM46 (3171)PYun et al. (2011) C 76 76/27 (1098) 61/0 NM NM NM NM 36 NM NM21/45 (2964)22.three (7.096.0) 21/0 2/19 2/19 18/43 (2062)14.Formula of 4-Bromo-7-(trifluoromethyl)quinoline six (six.027.0) 21/0 1/20 3/18 17/4 3/13/5 20/55/48 (3068) 25a 55/0 NM NM NM NM NM NM 28 0 046 (3069) 25a 76/0 NM NM NM NM NM NM 45 0 0Baseline Viral Status HBeAg, /HBcAb, /HBeAb, /NM NMNM NM NMHBcAg, //missing HBVDNA, log copies/ml Taxane Primarily based OthersNM 3.11a five 52.57a 4 26.1606b 22/14/5 21/3.9906bChemotherapy Regimen Anthracyline and Taxane Primarily based Form of TrialAnthracyline BasedNM NM NMNM NM NMFour studies with 285 sufferers had been integrated in this study (12, 23, 25, 26). One particular study was the potential randomized controlled study (25), the other two studies have been longitudinal historic controlled research (12) plus the remaining one particular is retrospective controlled study (26). The baseline characteristics of your 4 incorporated studies have been summarized in Table 1. All of the sufferers of 4 studies have been from East Asia, three (12, 23, 25) from China and one (26) from Korea. The 4 studies (12, 23, 25, 26) concentrated on breast cancer sufferers with HBsAg optimistic and only two (12, 25) provided the baseline HBV, DNA before chemotherapy. There had been no significant differences amongst baseline study characteristics with regards to patients’ age and baseline ALT before chemotherapy in between the prophylactic and the control group in 4 research. Chemotherapeutic regimens were not significantly different in three research (12, 25, 26), but a greater proportion of anthracyclinebased chemotherapeutic regimens in the prophylactic group had been located when compared with the manage group in a single study (23). The intriguing outcomes incorporated inside the metaanalysis have been shown in Table 2.Abbreviations: ALT, alanine aminotransferase; C, the handle group; NM, nonmentioned; P, the prophylactic lamivudine group a Imply b MedianRandomized controlled study1016Historic controlled studyHistoric controlled studyRetrospective controlled studyThere were important variations in counterpart groups in different outcomes, including price of HBV reactivation [2.6-Fluorobenzofuran-2-carboxylic acid Chemical name five vs.PMID:33586544 27.5 pooled OR = 0.09, 95 CI (0.03, 0.26), P 0.0001] (Table 3), incidence of hepatitis [11.9 vs. 41.three , pooled OR = 0.23, 95 CI (0.06, 0.92), P = 0.04] (Table three), incidence of hepatitis attributable to HBV reactivation [2.five vs. 23.5 , pooled OR = 0.10, 95 CI (0.03, 0.32), P 0.0001] (Table 3) and rate of chemotherapy disruption attributable to HBV reactivation [0.01 vs. 12.7 , pooled OR = 0.11, 95 CI (0.02, 0.58), P = 0.01] (Table 3). It is recommended that the outcomes were in favor in the prophylactic lamivudine group. Heterogeneity was not identified within the rate of HBV reactivation (P = 0.eight.
